Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331232

Institution ID

3331232

Institution full name and acronym

University of Bordeaux

Institution countries

France

Type of institution

Educational Institution

ENCePP partner

No
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

An observational post-authorization safety study to describe the safety of ustekinumab and other treatments of ulcerative colitis in a cohort of patients with ulcerative colitis using the French Nationwide claims database (SNDS) France
Cardiovascular-Renal-Metabolism comorbidity epidemiology and healthcare utilisation – Observational studies across Europe – French part of the study program (CaReMe Europe)
Comparative assessment of venous thromboembolism and other risks among patients with rheumatoid arthritis treated with baricitinib versus tumor necrosis factor inhibitors - French part of the study program (Safety Outcomes in Patients Treated for RA)
DARWIN EU® Natural history of dermatomyositis (DM) and polymyositis (PM) in adults and paediatric populations
Definition and validation of algorithms for the identification of specific clinical markers of multiple sclerosis using SNDS data (DIONISOS)
Dual antiplatelet therapy for prolonged secondary prevention of acute coronary events (DEEPSPACE)
Methods for controlling by indication for prescriptions: application to medications for neuropathic pain
Novel statistics to handle rare diseases and small sample sizes using Bayesian techniques: Application to Multiple Sclerosis (MS) and Systemic Lupus Erythematosus (SLE) in pregnancy
Programme d’évaluation de la vaccination COVID-19 : Risque d’effets indésirables d’intérêt des différents vaccins et comparaison du bénéfice-risque des vaccins (EVACOV-RISC)
Prospective, multi-country, observational registry to collect clinical
Study on feeling according to the patient of allergens specially prepared for individuals (allergenic ‘Named Patient Products’ NPPs) (ERAPP)